Can a new injection help shed pounds? a trial investigates

NCT ID NCT07752979

Not yet recruiting Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This clinical trial is testing an experimental drug called ABBV-295 to see if it can help adults with obesity or overweight lose weight. The study will compare different doses of the drug against a placebo (a dummy injection) to measure its effect on body weight over 32 weeks. Participants will receive weekly injections for about a year, and researchers will monitor their health and any side effects. The trial aims to find out if this new treatment could be a safe and effective option for chronic weight management.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABBV-295, an investigational long-acting amylin analog, given as a subcutaneous injection
What this could lead to: If successful, this could lead to a new treatment option for chronic weight management in people with obesity or overweight, potentially helping to reduce weight and improve related health conditions.
What could go wrong: This is an early-stage (Phase 2) trial, so the drug may not prove effective or safe. Side effects are possible, and the results may not lead to a widely available treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT

More trials for these conditions

Other studies related to the condition(s) this trial covers.